eMedicine Specialties > Neurology > Neuro-oncology

Benign Skull Tumors: Treatment & Medication

Author: Draga Jichici, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Contributor Information and Disclosures

Updated: Oct 13, 2009

Treatment

Medical Care

  • Administer aspirin or NSAIDs for osteoid osteoma.
  • Provide pain control symptomatically.
  • No treatment is required for asymptomatic lesions unless diagnostic concerns exist.

Surgical Care

  • Complete surgical excision is possible for symptomatic relief, cosmetic reasons, or cranial nerve decompression.
  • En bloc resection is the preferred intervention.
  • Curettage is also performed for lesions that cannot be resected completely. Careful removal of the cyst wall is critical in epidermoids and dermoids. Gamma Knife and CyberKnife are possible new ways of treating unresectable symptomatic lesions.7

Consultations

  • Neurosurgeon
  • Plastic surgeon
  • Neurologist
  • Radiation oncologist: Radiation therapy is acceptable as a second form of treatment in some partially resected lesions such as ossifying fibroma, hemangioma, and aneurysmal bone cyst because of their high recurrence rate. In addition, the Gamma Knife and the CyberKnife are under investigation.
  • Ophthalmologist

Medication

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known but may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms may exist as well, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.


Ibuprofen (Motrin, Advil, Haltran, Nuprin)

DOC for mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Adult

200-800 mg PO q6-8h while symptoms persist; not to exceed 3.2 g/d

Pediatric

<6 months: Not established
6 months to 12 years: 20-70 mg/kg/d PO divided tid/qid; start at lower end of dosing range and titrate; not to exceed 2.4 g/d
>12 years: Administer as in adults

May decrease effects of loop diuretics; may increase PT in patients taking anticoagulants (monitor PT carefully and watch patient for signs of bleeding); may increase serum lithium levels and risk of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity); probenecid may increase concentrations and probably toxicity of NSAIDs; consider effects on platelet function and gastric mucosa

Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Caution in congestive heart failure, hypertension, and decreased renal or hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy (monitor PT); acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion are at greatest risk of acute renal failure; low WBCs are rare and transient (usually return to normal as therapy continues); persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuing drug

Narcotics

Pain control is essential to quality patient care. These agents ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have moderate to severe pain.


Acetaminophen with codeine (Tylenol #3)

Indicated for treatment of mild to moderate pain.

Adult

15-60 mg PO q4h prn pain

Pediatric

0.5-1 mg/kg/dose PO q4-6h prn pain

Toxicity increases with CNS depressants or TCAs

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Significant abuse potential; may cause withdrawal headaches; may result in acute opiate withdrawal symptoms in patients dependent on opiates; caution in severe renal or hepatic dysfunction; babies born to mothers using narcotics regularly may show signs of withdrawal; be aware of total daily dose of acetaminophen; do not exceed 4000 mg/24h of acetaminophen; higher doses may cause liver toxicity


Oxycodone and acetaminophen (Percocet)

Drug combination indicated for relief of moderate to severe pain; DOC for aspirin-hypersensitive patients.

Adult

1-2 tab or cap PO q4-6h prn pain

Pediatric

0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose oxycodone

Phenothiazines may decrease analgesic effects; toxicity increases with coadministration of either CNS depressants or TCAs

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Duration of action may increase in elderly patients; be aware of total daily dose of acetaminophen; do not exceed 4000 mg/24h of acetaminophen; higher doses may cause liver toxicity


Hydrocodone bitartrate and acetaminophen (Vicodin ES)

Drug combination indicated for moderate to severe pain.

Adult

1-2 tab or cap PO q4-6h prn pain

Pediatric

<12 years: 10-15 mg/kg/dose acetaminophen q4-6h prn; not to exceed 2.6 g/d acetaminophen
>12 years: 750 mg acetaminophen q4h; not to exceed 10 mg hydrocodone bitartrate per dose or 5 doses/24h

Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or TCAs

Documented hypersensitivity; elevated intracranial pressure

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Tablets contain metabisulfite, which may cause allergic reactions; caution in severe renal or hepatic dysfunction; be aware of total daily dose of acetaminophen; do not exceed 4000 mg/24h of acetaminophen; higher doses may cause liver toxicity

Salicylates

Can reduce inflammation and pain symptoms.


Aspirin (Anacin, Ascriptin, Bayer Aspirin)

Treats mild to moderate pain and headache. Inhibits prostaglandin synthesis, which prevents formation of platelet-aggregating thromboxane A2.

Adult

325-650 mg PO q4-6h for osteoid osteoma

Pediatric

Not established

Effects may decrease with antacids and urinary alkalinizers; corticosteroids decrease salicylate serum levels; additive hypoprothrombinemic effects and increased bleeding time may occur with coadministration of anticoagulants; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses > 2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs

Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; use in children ( <16 y) with flu because of association of aspirin with Reye syndrome

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

May cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in patients with severe anemia, with history of blood coagulation defects, or who are taking anticoagulants

More on Benign Skull Tumors

Overview: Benign Skull Tumors
Differential Diagnoses & Workup: Benign Skull Tumors
Treatment & Medication: Benign Skull Tumors
Follow-up: Benign Skull Tumors
Multimedia: Benign Skull Tumors
References
Further Reading

References

  1. Yuca K, Kiris M, Avcu S, Bayram I, Cankaya H, Kiroglu AF. A giant paediatric mandibular aneurysmal bone cyst and reconstruction with bilateral iliac bone graft. B-ENT. 2009;5(1):39-42. [Medline].

  2. Nasser MJ. Psammomatoid ossifying fibroma with secondary aneurysmal bone cyst of frontal sinus. Childs Nerv Syst. May 30 2009;[Medline].

  3. Docquier PL, Delloye C, Galant C. Histology can be predictive of the clinical course of a primary aneurysmal bone cyst. Arch Orthop Trauma Surg. May 9 2009;[Medline].

  4. Konishi E, Okubo T, Itoi M, Katsumi Y, Murata H, Yanagisawa A. Chondroblastoma of trapezium with metacarpal involvement. Orthopedics. Apr 2008;31(4):395. [Medline].

  5. Schmitz-Feuerhake I, Pflugbeil S, Pflugbeil C. Radiation Risks from Diagnostic Radiology: Meningiomas and other Late Effects after Exposure of the Skull. Gesundheitswesen. Jun 23 2009;[Medline].

  6. Wootton-Gorges SL. MR imaging of primary bone tumors and tumor-like conditions in children. Magn Reson Imaging Clin N Am. Aug 2009;17(3):469-87, vi. [Medline].

  7. Dassoulas K, Schlesinger D, Yen CP, Sheehan J. The role of Gamma Knife surgery in the treatment of skull base chordomas. J Neurooncol. Mar 11 2009;[Medline].

  8. Burger PC, Scheithauer BW, Vogel FS. 4th ed. Surgical Pathology of the Nervous System and its Coverings. New York, NY: Churchill Livingstone; 2002:1-66.

  9. Huvos AG. Bone Tumors: Diagnosis, Treatment and Prognosis. Philadelphia, Pa: WB Saunders Company; 1979.

  10. Keyserling H, Peterson K, Camacho D, Castillo M. Giant cell angiofibroma of the orbit. AJNR Am J Neuroradiol. Aug 2004;25(7):1266-8. [Medline].

  11. Mirra JM. Bone Tumors: Clinical, Radiological and Pathological Correlations. Philadelphia, Pa: Lea and Febiger; 1989.

  12. Morris JM, Lane JI, Witte RJ, Thompson DM. Giant cell reparative granuloma of the nasal cavity. AJNR Am J Neuroradiol. Aug 2004;25(7):1263-5. [Medline].

  13. Thomas JE, Baker HL Jr. Assessment of roentgenographic lucencies of the skull: a systematic approach. Neurology. Feb 1975;25(2):99-106. [Medline].

  14. Unni KK. 5th ed. Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996.

  15. Wilkins RH, Rengachary SS. 2nd ed. Neurosurgery. New York, NY: McGraw-Hill; 1996:1503-1528.

  16. Youmans JR. 5th ed. Neurological Surgery. Philadelphia, Pa: WB Saunders Company; 2004:3227-3268.

Keywords

skull, tumor, aneurysmal bone cyst, bone-forming tumor, chondroma, chondroblastoma, chondromyxoid fibroma, connective tissue tumor, desmoplastic fibroma, dermoid, encephalocele, eosinophilic granuloma, epidermoid, fibrous dysplasia, giant cell granuloma, Gardner's syndrome, Hand-Schüller-Christian disease, hemangioma, lymphangioma, Maffucci's syndrome, McCune-Albright's syndrome, meningoencephalocele, nonossifying fibroma, Ollier's syndrome, ossifying fibroma, osteoblastoma, osteoid osteoma, osteoma, pacchionian depression, venous lakes of the skull, xanthoma

Contributor Information and Disclosures

Author

Draga Jichici, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Disclosure: Nothing to disclose.

Medical Editor

Spiros Manolidis, MD, Associate Professor of Otolaryngology and Neurological Surgery, Columbia University
Spiros Manolidis, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Auditory Society, American Head and Neck Society, American Medical Association, Canadian Society of Otolaryngology-Head & Neck Surgery, Society of University Otolaryngologists-Head and Neck Surgeons, and Texas Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Jorge Kattah, MD, Head, Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria
Jorge Kattah, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, and New York Academy of Sciences
Disclosure: Biogen Honoraria Consulting; Bayer Corporation Honoraria Consulting

Chief Editor

Nicholas Y Lorenzo, MD, Chief Editor, eMedicine Neurology; Consulting Staff, Neurology Specialists and Consultants
Nicholas Y Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Neurology
Disclosure: Nothing to disclose.

RELATED EMEDICINE ARTICLES
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.